1. Immunoreactivity against fibroblast growth factor 8 in alveolar rhabdomyosarcoma patients and its involvement in tumor aggressiveness
   Elena Poli et al, 2022, OncoImmunology CrossRef
2. Matrine inhibits cell proliferation and induces apoptosis of human rhabdomyosarcoma cells via downregulation of the extracellular signal-regulated kinase pathway
   Penghui Yan et al, 2017, Oncology Letters CrossRef
3. In ovo chorioallantoic membrane assay as a xenograft model for pediatric rhabdomyosarcoma
   Chika Shoji et al, 2023, Oncology Reports CrossRef
4. Potential Mechanisms of Yanghe Decoction in the Treatment of Soft Tissue Sarcoma and Arteriosclerosis Obliterans Based on Network Pharmacology
   Yiran Zhai et al, 2022, Chinese medicine and natural products CrossRef
5. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma
   David Milewski et al, 2021, Oncogene CrossRef
6. Signaling pathways in Rhabdomyosarcoma invasion and metastasis
   Farah Ramadan et al, 2020, Cancer and Metastasis Reviews CrossRef
7. Inhibition of lipid metabolism exerts antitumor effects on rhabdomyosarcoma
   Satoshi Miyagaki et al, 2021, Cancer Medicine CrossRef
8. The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines
   Andreas Schmidt et al, 2021, Cancers CrossRef
9. Rhabdomyosarcoma
   Stephen X. Skapek et al, 2019, Nature Reviews Disease Primers CrossRef
10. Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma
    Norio Nakagawa et al, 2019, Biochemical and Biophysical Research Communications CrossRef
11. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1‐driven and independent disease‐promoting gene expression in fusion‐positive Rhabdomyosarcoma
    Lays M. Sobral et al, 2020, Molecular Oncology CrossRef
12. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario
    Marina Ferreira Candido et al, 2023, Pharmaceutics CrossRef